Volume 26, Issue 2 (5-2019)
RJMS 2019, 26(2): 1-9 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Talebi Taher M, Minaeian S, Bahadorizadeh L, Moradians V, Moradimoghadam O, asadipanah M et al . Ventilator Associated Pneumonia by Acinetobacter baumannii And antimicrobial susceptibility pattern. RJMS 2019; 26 (2) :1-9
URL: http://rjms.iums.ac.ir/article-1-5320-en.html
URL: http://rjms.iums.ac.ir/article-1-5320-en.html
Mahshid Talebi Taher 
, Sara Minaeian , Leila Bahadorizadeh , Vahan Moradians , Omid Moradimoghadam , Mohamadreza Asadipanah , Yasaman Hendi
, Sara Minaeian , Leila Bahadorizadeh , Vahan Moradians , Omid Moradimoghadam , Mohamadreza Asadipanah , Yasaman Hendi
Iran University of Medical Sciences, Tehran, Iran , talebitaher.m@iums.ac.ir
Abstract: (4222 Views)
Background: Ventilator Associated Pneumonia (VAP) is one of the serious complications of ventilator support occurring in ICUs. The aim of this study was to determine the susceptibility pattern of Acinetobacter baumannii (A. baumannii) isolated from patients with VAP by two methods: disk diffusion and E. test.
Methods: This descriptive-cross sectional study was conducted in the four ICUs of Rasoul-e-Akram Hospital in Tehran, from October 2016 to November 2017. A total of 58 endobronchial aspirates from intubated patients who had been clinically diagnosed to have VAP by A. baumannii were studied. The in vitro susceptibility was determined by disk-diffusion and broth microdilution MIC methods. The results were used in chi2 assay to express a meaningful relationship. P<0.05 was considered statistically significant.
Results: With the E. test method high percentage of isolates were resistant to levofloxacin (100%), carbapenems (meropenem: 93.10%, imipenem 70.69%), piperacillin-tazobactam (50%) and aminoglycosides (gentamicin 41.38%). The most sensitive antibiotic was colistin.
Conclusion: Antimicrobial resistance to A. baumannii in ICUs is increasing, and the findings of the study have shown that colistin is the only drug with relative efficacy.
Methods: This descriptive-cross sectional study was conducted in the four ICUs of Rasoul-e-Akram Hospital in Tehran, from October 2016 to November 2017. A total of 58 endobronchial aspirates from intubated patients who had been clinically diagnosed to have VAP by A. baumannii were studied. The in vitro susceptibility was determined by disk-diffusion and broth microdilution MIC methods. The results were used in chi2 assay to express a meaningful relationship. P<0.05 was considered statistically significant.
Results: With the E. test method high percentage of isolates were resistant to levofloxacin (100%), carbapenems (meropenem: 93.10%, imipenem 70.69%), piperacillin-tazobactam (50%) and aminoglycosides (gentamicin 41.38%). The most sensitive antibiotic was colistin.
Conclusion: Antimicrobial resistance to A. baumannii in ICUs is increasing, and the findings of the study have shown that colistin is the only drug with relative efficacy.
Type of Study: Research |
Subject:
Infectious Disease
References
2. 1. Ghazvini K, Ghanaat J, Malek Jafarian M, Yazdan Panah M, Irani N. Incidence of nosocomial pneumonia and bacterial agents causing this infection in intensive care unit in Ghaem educational university hospital in Mashhad. J Ilam Uni Med Sci; 2005.13(4):55-61.
3. 2. Joseph NM, Sistla S, Dutta TK, Badhe AS, Parija SC. Ventilator-associated pneumonia in a tertiary care hospital in India: incidence and risk factors. J Infect Dev Ctries; 2009.3(10): 771-7.
4. 3. Gopal Katherason S, Naing L, Jaalam K, Imran Musa K, Nik Mohamad NA, Aiyar S, et al. Ventilator-associated nosocomial pneumonia in intensive care units in Malaysia. J Infect Dev Ctries; 2009.3(9):704-10.
5. 4. da Silva JM Jr, Rezende E, Guimarães T, dos Campos EV, Magno LA, Consorti L, et al. Epidemiological and microbiological analysis of ventilator-associated pneumonia patients in a public teaching hospital. Braz J Infect Dis; 2007.11(5):482-8.
6. 5. Phu VD, Nadjm B, Duy NHA, Co DX, Mai NTH, Trinh DT, et al. Ventilatoe-associated respiratory infection in a resource-restricted setting: impact and etiology. J Intensive Care; 2017.5:69.
7. 6. Wang H, Guo P, Sun H, Wang H, Yang Q, Chen M, et al. Molecular epidemiology of clinical isolates of carbapenem-resistant Acinetobacter spp. from Chinese hospitals. Antimicrob Agents Chemother; 2007.51(11):4022-28.
8. 7. Bergogne-Berezin E, Towner KJ. Acinetobacter spp. as nosocomial pathogens: Microbiological, clinical, and epidemiological features. Clin Microbiol Rev; 1996.9(2):148-65.
9. 8. Van Looveren M, Goossens H; ARPAC Steering Group. Antimicrobial resistance of Acinetobacter spp. in Europe. Clin Microbiol Infect; 2004.10(8):684-704.
10. 9. Coelho J, Woodford N, Turton J, Livermore DM. Multiresistant acinetobacter in the UK: how big a threat? J Hosp Infect; 2004.58(3):167-9.
11. 10. Zarrilli R, Crispino M, Bagattini M, Barretta E, Di Popolo A, Triassi M, et al. Molecular epidemiology of sequential outbreaks of Acinetobacter baumannii in an intensive care unit shows the emergence of carbapenem resistance. J Clin Microbiol; 2004.42(3):946-53.
12. 11. Talebi-Taher M, Latifnai M, Adabi M, Rastgar-Lari A, Fatahi M, Babazadeh Sh. Risk factors and antimicrobial susceptibility in ventilator associated pneumonia: a brief report. Tehran Uni Med J; 2012.70(9):577-82.
13. 12. Hashemi SH, Hashemi N, Esna-Ashari F, Taher A, Dehghan A. Clinical features and antimicrobial resistance of bacterial agents of ventilator associated tracheobronchitis in Hamedan, Iran. Oman Med J; 2017.32(5):403-8.
14. 13. Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA, Palmer LB, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia, 2016 clinical
15. practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis; 2016.63(5):e61-e111.
16. 14. Cook D, Walter S, Cook R, Griffith L, Guyatt G, Leasa D, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med; 1998.129(6):433-40.
17. 15. Tejarina E, Frutos-vivar F, Restrepo MI, Anzuet A, Abroug F, Palizes F, et al. Incidence and risk factor, and outcome of ventilator-associated pneumonia. J Crit Care; 2006.21(11):56-65.
18. 16. Nassaji M, Mousavi Sh, Ghorbani R. Incidence of nosocomial pneumonia in patients older than 15 years old in ICUs Semnan University of Medical Sciences. J Semnan Univ Med Sci; 2003.5(1-2):87-92.
19. 17. Restrepo Ml, Peterson J, Fernandez JF, Qin Z, Fisher AC, Nicholson SC. Comparison of the bacterial etiology of early-onset and late-onset ventilator associated pneumonia in subjects enrolled in 2 large clinical studies. Respir Care; 2013.58(7):1220-5.
20. 18. Prashanth K, Badrinath S. In vitro susceptibility pattern of Acinetobacter species to commonly used cephalosporins, quinolones, and aminoglycosides. Indian J Med Microbiol; 2004.22:97-103.
21. 19. Angoti G, Godarzi H, Besharat M, Hajizadeh M, Zarringhalam-Moghaddam M. Evaluation of antibiotic resistance of clinical Acinetobacter baumanii isolated of Tabriz hospital by disk diffusion and MIC. Res Med; 2012.38(2):106-10.
22. 20. Farahani Kheltabadi R, Moniri R, Shajari GR, Nazem Shirazi MH, Musavi SGA, Ghasemi A, et al. Antimicrobial susceptibility patterns and the distribution of resistance genes among Acinetobacter species isolated from patients in Shahid Beheshti Hospital, Kashan. Feyz; 2009.12(4):61-7.
23. 21. Li Q, Gong X. Clinical significance of the detection of procalcitonin and C-reactive protein in the intensive care unit. Exp Ther Med; 2018.15(5):4265-70.
24. 22. Jiao J, Wang M, Zhang J, Shen K, Liao X, Zhou X. Procalcotonin as a diagnostic marker of ventilator-associated pneumonia in cardiac surgery patients. Exp Ther Med; 2015.9(3):1051-57.
25. 23. Povoa P, Martin-Loeches I, Ranirez P, Bos LD, Esperatti M, Silvestre J, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care; 2016.6(1):32.
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
